Tvardi Therapeutics (TVRD) EPS (Basic) (2013 - 2026)
Tvardi Therapeutics (TVRD) posted EPS (Basic) of -$0.81 for Q1 2026, up 31.29% sequentially from -$1.17 in Q4 2025, and up 87.19% YoY from -$0.43 in Q1 2025.
Tvardi Therapeutics (TVRD) EPS (Basic) (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported EPS (Basic) for 14 years, with the latest figure at -$0.81 in Q1 2026.
- Quarterly EPS (Basic) rose 87.19% year-over-year to -$0.81 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.76 (up 64.18% YoY) and the FY2025 annual result came in at -$3.75, up 91.95% from the prior year.
- EPS (Basic) rose to -$0.81 in Q1 2026 per TVRD's latest filing, from -$1.17 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$0.81 in Q1 2026 and troughed at -$22.01 in Q4 2023.
- A 5-year average of -$11.94 and a median of -$7.05 in 2024 frame the typical range for EPS (Basic).
- The sharpest annual moves came in 2022 and 2026: EPS (Basic) slumped 2324.59% in 2022, then surged 87.19% in 2026.
- Over 5 years, EPS (Basic) stood at -$21.34 in 2022, then fell by 3.16% to -$22.01 in 2023, then surged by 67.98% to -$7.05 in 2024, then soared by 83.38% to -$1.17 in 2025, then jumped by 31.29% to -$0.81 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$0.81, -$1.17, and -$4.27 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 0.18 |
| 10 | Tvardi Therapeutics | 17.73 Mn | 17.73 Mn | - | -0.69 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.81 |
| Dec 31, 2025 | -1.17 |
| Sep 30, 2025 | -4.27 |
| Jun 30, 2025 | -3.14 |
| Mar 31, 2025 | -6.28 |
| Dec 31, 2024 | -7.05 |
| Sep 30, 2024 | -6.48 |
| Jun 30, 2024 | -4.67 |
| Mar 31, 2024 | -20.46 |
| Dec 31, 2023 | -22.01 |
| Sep 30, 2023 | -20.11 |
| Jun 30, 2023 | -21.89 |
| Mar 31, 2023 | -19.48 |
| Dec 31, 2022 | -21.34 |
| Sep 30, 2022 | -17.64 |
| Jun 30, 2022 | -5.00 |
| Mar 31, 2022 | -21.11 |
| Dec 31, 2021 | -23.70 |
| Sep 30, 2021 | -0.73 |
| Jun 30, 2021 | -22.11 |